ペットがん治療薬の世界市場レポート 2025年

ペットがん治療薬の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR10.7％で6億5,000万米ドルに成長します。予測期間の成長は、ペットの高齢化、がん治療の進歩、獣医腫瘍学サービスの増加、ペット保険とヘルスケアプラン、ペットケアサービスの世界の拡大が要因です。予測期間の主な動向には、栄養補助食品や統合療法の増加、標的診断検査の利用可能性の増加、獣医とヒトの腫瘍学の連携、新規化学療法剤の導入、意識の高まりと飼い主教育が含まれます。

ペットヘルスケア支出の増加が予想されることから、ペットがん治療薬市場の拡大が見込まれます。ペットのヘルスケア支出には、獣医サービス、投薬、その他ペットのヘルスケア関連費用に充てられる資金が含まれます。ペットの健康に投資しようという飼い主の動向の高まりが、ペットヘルスケアへの支出増に反映され、ペットがん治療薬の需要増につながっています。例えば、North American Pet Health Insurance Association（NAPHIA）の2023 State of the Industry Reportでは、2022年末までに米国で保険に加入するペットの総数が2021年比で22％増加し、480万匹に達することが明らかにされています。このペットヘルスケア支出の急増がペットがん治療薬市場の原動力となっています。

ペットがん治療薬市場の成長は、ペットがんの有病率の増加によって推進されると予想されます。ペットがんは、家畜の異常で制御不能な細胞増殖を伴い、腫瘍形成につながります。ペットがんの罹患率の増加は、環境毒素、汚染物質、遺伝的およびライフスタイル要因に起因しています。その結果、ペット用の高度で効果的ながん治療薬に対する需要が高まっています。獣医がん協会（VCS）の2022年予測によると、犬の約4匹に1匹が一生の間にがんと診断され、高齢のペットではがんが主な死因となっています。また、米国国立がん研究所は、ペットの新たながん患者は年間約600万人と予測しており、今後数年で増加すると予測しています。ペットのがん罹患率の増加は、ペットがん治療薬市場の成長を牽引するものと考えられます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ペットがん治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、制約）
• 最終用途産業の分析
• 世界のペットがん治療薬市場：成長率分析
• 世界のペットがん治療薬市場の実績：規模と成長, 2019-2024
• 世界のペットがん治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界ペットがん治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のペットがん治療薬市場がんの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 悪性黒色腫
• 肥満細胞がん
• リンパ腫
• 乳腺がんおよび扁平上皮がん
• 世界のペットがん治療薬市場：種別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 犬
• 猫
• その他の種
• 世界のペットがん治療薬市場セラピーによって、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 放射線治療
• 免疫療法
• トモセラピー
• その他の治療法
• 世界のペットがん治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 動物病院
• 臨床薬局
• 小売薬局
• オンライン薬局
• その他のエンドユーザー
• 世界のペットがん治療薬市場、メラノーマのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外科的介入
• 化学療法
• 免疫療法
• 標的療法
• 世界のペットがん治療薬市場、肥満細胞がんの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 手術
• 化学療法
• チロシンキナーゼ阻害剤
• 放射線治療
• 世界のペットがん治療薬市場、リンパ腫のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法プロトコル
• ステロイド療法
• 放射線治療
• 免疫療法
• 世界のペットがん治療薬市場乳腺がんおよび扁平上皮がんの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外科的治療
• 化学療法
• 放射線治療
• 緩和ケアの選択肢

第7章 地域別・国別分析

• 世界のペットがん治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のペットがん治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ペットがん治療薬市場：競合情勢
• ペットがん治療薬市場：企業プロファイル
  • AB Science Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim GmbH Overview, Products and Services, Strategy and Financial Analysis
  • Elanco Animal Health Overview, Products and Services, Strategy and Financial Analysis
  • ELIAS Animal Health Overview, Products and Services, Strategy and Financial Analysis
  • Zoetis Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Anivive Lifesciences Inc.
• QBiotics Group Ltd.
• Regeneus Ltd.
• VetDC Inc.
• PetCure Oncology at Veterinary Radiosurgery and Imaging Center
• Torigen Pharmaceuticals Inc.
• virology and bacteriology
• Nippon Zenyaku Kogyo Co. Ltd.
• Vivesto AB
• Dechra Pharmaceuticals plc
• Norbrook Laboratories Ltd.
• AdvaVet Inc.
• Oasmia Pharmaceuticals AB
• Zenoaq Co. Ltd.
• Morphogenesis Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ペットがん治療薬市場2029：新たな機会を提供する国
• ペットがん治療薬市場2029：新たな機会を提供するセグメント
• ペットがん治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Pet cancer therapeutics involve the use of various treatments and medications to manage or cure cancer in pets. The choice of therapeutics depends on several factors such as the type and stage of cancer, as well as the pet's age and overall health.

The main types of pet cancer therapeutics are tailored to specific cancer types, including melanoma, mast cell cancer, lymphoma, and mammary and squamous cell cancer. Melanoma is a type of cancer that originates from pigment-producing cells called melanocytes. These therapeutics can be administered through various routes, including oral and injection methods, tailored for dogs, cats, and other animals. Different therapies employed in pet cancer treatment include chemotherapy, radiation therapy, immunotherapy, tomo therapy, and others. These therapies are utilized by veterinary hospitals, clinical pharmacies, retail pharmacies, online pharmacies, and other healthcare facilities focused on pet health.

The pet cancer therapeutics market research report is one of a series of new reports from The Business Research Company that provides pet cancer therapeutics market statistics, including pet cancer therapeutics industry global market size, regional shares, competitors with a pet cancer therapeutics market share, detailed pet cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the pet cancer therapeutics industry. This pet cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pet cancer therapeutics market size has grown rapidly in recent years. It will grow from $0.39 billion in 2024 to $0.43 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to rise in pet ownership, advancements in veterinary medicine, increased awareness of pet health, humanization of pets, expansion of veterinary services.

The pet cancer therapeutics market size is expected to see rapid growth in the next few years. It will grow to $0.65 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to growing aging pet population, advancements in cancer treatment, rising veterinary oncology services, pet insurance and healthcare plans, global expansion of pet care services. Major trends in the forecast period include rise in nutraceuticals and integrative therapies, increased availability of targeted diagnostic tests, collaboration between veterinary and human oncology, introduction of novel chemotherapeutic agents, growing awareness and pet owner education.

The anticipated growth in pet healthcare expenditure is set to drive the expansion of the pet cancer therapeutics market. Pet healthcare expenditure encompasses the funds allocated for veterinary services, medications, and other healthcare-related costs for pets. The rising trend of pet owners' willingness to invest in their pets' well-being is reflected in the increased expenditure on pet healthcare, leading to a higher demand for pet cancer therapeutics. For example, the North American Pet Health Insurance Association's (NAPHIA) 2023 State of the Industry Report revealed a 22% increase in the total number of insured pets in the U.S. by the end of 2022, reaching 4.8 million, compared to 2021. This surge in pet healthcare expenditure is a driving force for the pet cancer therapeutics market.

The growth of the pet cancer therapeutics market is expected to be propelled by the increasing prevalence of pet cancer. Pet cancer involves abnormal and uncontrolled cell growth in domesticated animals, leading to tumor formation. The rising incidence of pet cancer is attributed to environmental toxins, pollutants, and genetic and lifestyle factors. Consequently, there is an escalating demand for advanced and effective cancer therapeutics for pets. According to the Veterinary Cancer Society's (VCS) 2022 predictions, approximately 1 in 4 dogs is diagnosed with cancer during their lifetime, with cancer being a primary cause of death among older pets. Additionally, the National Cancer Institute anticipates approximately 6 million new cancer cases in pets annually, with a projected increase in the coming years. The increasing prevalence of pet cancer is poised to drive the growth of the pet cancer therapeutics market.

Leading companies in the pet cancer therapeutics market are focusing on developing epigenetic technologies to enhance the efficacy of treatments and improve precision in targeting cancer cells, ultimately leading to better outcomes for pets diagnosed with cancer. Epigenetic technology involves techniques that modify gene expression without altering the underlying DNA sequence, thereby influencing cellular behavior and therapeutic results. For example, in April 2024, VolitionRx Limited, a US-based multinational epigenetics company, launched the Nu.Q Vet Cancer Test. This test operates on the Element i+ Analyzer and delivers rapid results-typically within approximately six minutes. It employs an enzyme-linked immunosorbent assay to detect circulating nucleosomes in the blood, which can serve as indicators of cancer presence.

Strategic partnerships are a significant approach adopted by major companies in the pet cancer therapeutics market to achieve superior disease control. This collaborative strategy involves leveraging each other's strengths and resources to attain mutual benefits and success. One such collaboration occurred in June 2022, when Germany-based pharmaceutical company Boehringer Ingelheim partnered with U.S.-based biopharmaceutical company CarthroniX. The collaboration focuses on identifying new small molecules to target cancers in dogs, potentially offering superior disease control. CarthroniX will supply the small molecules for evaluation by Boehringer Ingelheim, emphasizing their commitment to advancing oncology research in animal health and exploring new therapeutic options for the treatment of canine cancer.

In June 2024, Lantheus, a US-based company specializing in the development and commercialization of innovative imaging products and radiopharmaceuticals for diagnostic purposes in healthcare, acquired Life Molecular Imaging GmbH for an undisclosed sum. This acquisition is intended to enhance Lantheus's portfolio of diagnostic imaging solutions, expand its capabilities in molecular imaging, and strengthen its position within the healthcare market. Life Molecular Imaging GmbH, based in Germany, is dedicated to advancing imaging technologies, particularly in the realm of molecular imaging.

Major companies operating in the pet cancer therapeutics market include AB Science, Boehringer Ingelheim GmbH, Elanco Animal Health, ELIAS Animal Health, Zoetis Inc., Anivive Lifesciences Inc., QBiotics Group Ltd., Regeneus Ltd., VetDC Inc., PetCure Oncology at Veterinary Radiosurgery and Imaging Center, Torigen Pharmaceuticals Inc., virology and bacteriology, Nippon Zenyaku Kogyo Co. Ltd., Vivesto AB, Dechra Pharmaceuticals plc, Norbrook Laboratories Ltd., AdvaVet Inc., Oasmia Pharmaceuticals AB, Zenoaq Co. Ltd., Morphogenesis Inc., Sumitomo Pharma Animal Health Co., Vetivax, CarthroniX Inc.

North America was the largest region in the pet cancer therapeutics market in 2024. The regions covered in the pet cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pet cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pet cancer therapeutics market consists of revenues earned by entities by surgery and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pet Cancer Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pet cancer therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pet cancer therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pet cancer therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Cancer Type: Melanoma; Mast Cell Cancer; Lymphoma; Mammary And Squamous Cell Cancer
• 2) By Species: Dogs; Cats; Other Species
• 3) By Therapy: Chemotherapy; Radiation Therapy; Immunotherapy; TomoTherapy; Other Therapies
• 4) By End User: Veterinary Hospitals; Clinical Pharmacies; Retail Pharmacies; Online Pharmacies; Other End Users
• Subsegments:
• 1) By Melanoma: Surgical Interventions; Chemotherapy; Immunotherapy; Targeted Therapy
• 2) By Mast Cell Cancer: Surgery; Chemotherapy; Tyrosine Kinase Inhibitors; Radiation Therapy
• 3) By Lymphoma: Chemotherapy Protocols; Steroid Therapy; Radiation Therapy; Immunotherapy
• 4) By Mammary And Squamous Cell Cancer: Surgical Treatment; Chemotherapy; Radiation Therapy; Palliative Care Options
• Companies Mentioned: AB Science; Boehringer Ingelheim GmbH; Elanco Animal Health; ELIAS Animal Health; Zoetis Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pet Cancer Therapeutics Market Characteristics

3. Pet Cancer Therapeutics Market Trends And Strategies

4. Pet Cancer Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Pet Cancer Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pet Cancer Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pet Cancer Therapeutics Market Growth Rate Analysis
• 5.4. Global Pet Cancer Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pet Cancer Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pet Cancer Therapeutics Total Addressable Market (TAM)

6. Pet Cancer Therapeutics Market Segmentation

• 6.1. Global Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Melanoma
• Mast Cell Cancer
• Lymphoma
• Mammary And Squamous Cell Cancer
• 6.2. Global Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dogs
• Cats
• Other Species
• 6.3. Global Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Radiation Therapy
• Immunotherapy
• TomoTherapy
• Other Therapies
• 6.4. Global Pet Cancer Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Veterinary Hospitals
• Clinical Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other End Users
• 6.5. Global Pet Cancer Therapeutics Market, Sub-Segmentation Of Melanoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgical Interventions
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• 6.6. Global Pet Cancer Therapeutics Market, Sub-Segmentation Of Mast Cell Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Chemotherapy
• Tyrosine Kinase Inhibitors
• Radiation Therapy
• 6.7. Global Pet Cancer Therapeutics Market, Sub-Segmentation Of Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy Protocols
• Steroid Therapy
• Radiation Therapy
• Immunotherapy
• 6.8. Global Pet Cancer Therapeutics Market, Sub-Segmentation Of Mammary And Squamous Cell Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgical Treatment
• Chemotherapy
• Radiation Therapy
• Palliative Care Options

7. Pet Cancer Therapeutics Market Regional And Country Analysis

• 7.1. Global Pet Cancer Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pet Cancer Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pet Cancer Therapeutics Market

• 8.1. Asia-Pacific Pet Cancer Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pet Cancer Therapeutics Market

• 9.1. China Pet Cancer Therapeutics Market Overview
• 9.2. China Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pet Cancer Therapeutics Market

• 10.1. India Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pet Cancer Therapeutics Market

• 11.1. Japan Pet Cancer Therapeutics Market Overview
• 11.2. Japan Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pet Cancer Therapeutics Market

• 12.1. Australia Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pet Cancer Therapeutics Market

• 13.1. Indonesia Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pet Cancer Therapeutics Market

• 14.1. South Korea Pet Cancer Therapeutics Market Overview
• 14.2. South Korea Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pet Cancer Therapeutics Market

• 15.1. Western Europe Pet Cancer Therapeutics Market Overview
• 15.2. Western Europe Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pet Cancer Therapeutics Market

• 16.1. UK Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pet Cancer Therapeutics Market

• 17.1. Germany Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pet Cancer Therapeutics Market

• 18.1. France Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pet Cancer Therapeutics Market

• 19.1. Italy Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pet Cancer Therapeutics Market

• 20.1. Spain Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pet Cancer Therapeutics Market

• 21.1. Eastern Europe Pet Cancer Therapeutics Market Overview
• 21.2. Eastern Europe Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pet Cancer Therapeutics Market

• 22.1. Russia Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pet Cancer Therapeutics Market

• 23.1. North America Pet Cancer Therapeutics Market Overview
• 23.2. North America Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pet Cancer Therapeutics Market

• 24.1. USA Pet Cancer Therapeutics Market Overview
• 24.2. USA Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pet Cancer Therapeutics Market

• 25.1. Canada Pet Cancer Therapeutics Market Overview
• 25.2. Canada Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pet Cancer Therapeutics Market

• 26.1. South America Pet Cancer Therapeutics Market Overview
• 26.2. South America Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pet Cancer Therapeutics Market

• 27.1. Brazil Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pet Cancer Therapeutics Market

• 28.1. Middle East Pet Cancer Therapeutics Market Overview
• 28.2. Middle East Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pet Cancer Therapeutics Market

• 29.1. Africa Pet Cancer Therapeutics Market Overview
• 29.2. Africa Pet Cancer Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pet Cancer Therapeutics Market, Segmentation By Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Pet Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pet Cancer Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Pet Cancer Therapeutics Market Competitive Landscape
• 30.2. Pet Cancer Therapeutics Market Company Profiles
  • 30.2.1. AB Science Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Boehringer Ingelheim GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Elanco Animal Health Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. ELIAS Animal Health Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Zoetis Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Pet Cancer Therapeutics Market Other Major And Innovative Companies

• 31.1. Anivive Lifesciences Inc.
• 31.2. QBiotics Group Ltd.
• 31.3. Regeneus Ltd.
• 31.4. VetDC Inc.
• 31.5. PetCure Oncology at Veterinary Radiosurgery and Imaging Center
• 31.6. Torigen Pharmaceuticals Inc.
• 31.7. virology and bacteriology
• 31.8. Nippon Zenyaku Kogyo Co. Ltd.
• 31.9. Vivesto AB
• 31.10. Dechra Pharmaceuticals plc
• 31.11. Norbrook Laboratories Ltd.
• 31.12. AdvaVet Inc.
• 31.13. Oasmia Pharmaceuticals AB
• 31.14. Zenoaq Co. Ltd.
• 31.15. Morphogenesis Inc.

32. Global Pet Cancer Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pet Cancer Therapeutics Market

34. Recent Developments In The Pet Cancer Therapeutics Market

35. Pet Cancer Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Pet Cancer Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pet Cancer Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pet Cancer Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer